Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus

Bárbara Soria-Juan; Natalia Escacena; Vivian Capilla-González; Yolanda Aguilera; Lucía Llanos; Juan R Tejedo; Francisco J Bedoya; Verónica Juan; Antonio De la Cuesta; Rafael Ruiz-Salmerón; Enrique Andreu; Lukas Grochowicz; Felipe Prósper; Fermín Sánchez-Guijo; Francisco S Lozano; Manuel Miralles; Lourdes Del Río-Solá; Gregorio Castellanos; José M Moraleda; Robert Sackstein; Mariano García-Arranz; Damián García-Olmo; Franz Martín; Abdelkrim Hmadcha; Bernat Soria; Collaborative Working Group “Noma Project Team”

doi:10.3389/fimmu.2020.02029

Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus

Front Immunol. 2020 Sep 2:11:2029. doi: 10.3389/fimmu.2020.02029. eCollection 2020.

Authors

Bárbara Soria-Juan¹, Natalia Escacena², Vivian Capilla-González², Yolanda Aguilera², Lucía Llanos¹, Juan R Tejedo^{2

3}, Francisco J Bedoya^{2

3}, Verónica Juan⁴, Antonio De la Cuesta⁵, Rafael Ruiz-Salmerón⁶, Enrique Andreu⁷, Lukas Grochowicz⁷, Felipe Prósper⁷, Fermín Sánchez-Guijo⁸, Francisco S Lozano⁸, Manuel Miralles⁹, Lourdes Del Río-Solá¹⁰, Gregorio Castellanos¹¹, José M Moraleda¹¹, Robert Sackstein¹², Mariano García-Arranz¹, Damián García-Olmo¹, Franz Martín^{2

3}, Abdelkrim Hmadcha^{2

3}, Bernat Soria^{2

3

13}; Collaborative Working Group “Noma Project Team”

Affiliations

¹ Fundación Jiménez Díaz Health Research Institute, Madrid, Spain.
² Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain.
³ Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.
⁴ Andalusian eHealth Library, Sevilla, Spain.
⁵ Unidad de Isquemia Crónica de Miembros Inferiores, Hospital Victoria Eugenia de la Cruz Roja, Sevilla, Spain.
⁶ Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, Spain.
⁷ Clínica Universidad de Navarra, Pamplona, Spain.
⁸ IBSAL-Hospital Universitario Salamanca, Salamanca, Spain.
⁹ Department of Surgery, University of Valencia, Valencia, Spain.
¹⁰ Cirugía Vascular, Hospital Universitario de Valladolid, Valladolid, Spain.
¹¹ Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
¹² Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.
¹³ ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, Spain.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2019.01151.].

Keywords: cell-based therapy; cellular medicaments; clinical trials; cost-effective; critical limb ischemia; diabetes.

Copyright © 2020 Soria-Juan, Escacena, Capilla-González, Aguilera, Llanos, Tejedo, Bedoya, Juan, De la Cuesta, Ruiz-Salmerón, Andreu, Grochowicz, Prósper, Sánchez-Guijo, Lozano, Miralles, Del Río-Solá, Castellanos, Moraleda, Sackstein, García-Arranz, García-Olmo, Martín, Hmadcha, Soria and the Collaborative Working Group “Noma Project Team”.

Publication types

Published Erratum